Pharvaris (PHVS) Other Operating Expenses (2021 - 2025)

Pharvaris (PHVS) reported Other Operating Expenses of -$0.0 for Q3 2025, up 100.0% quarter-over-quarter from -$67.0 million in Q2 2025.

Pharvaris (PHVS) Other Operating Expenses (2021 - 2025) Analysis & Trends

Pharvaris has reported Other Operating Expenses for 5 years, with the latest figure at -$0.0 in Q3 2025.

For the quarter ending Q3 2025, Other Operating Expenses changed N/A year-over-year to -$0.0; the trailing twelve-month figure through Mar 2026 stood at -$67.0 million (down 34.52% YoY), and the FY2024 full-year result was -$149066.1, down 1044.91% from the prior year.
Other Operating Expenses for Q3 2025 stood at -$0.0, up from -$67.0 million in the prior quarter.
The five-year high for Other Operating Expenses was $261755.4 in Q4 2021, with the low at -$67.0 million in Q2 2025.
Historically, Other Operating Expenses has averaged -$14.1 million across 5 years, with a median of -$474.39 in 2022.
Annual changes were most pronounced in 2022 — Other Operating Expenses plunged 50937568259300.0% — and 2023, when it retreated 9.19%.
Pharvaris' Other Operating Expenses stood at $261755.4 in 2021, then plunged by 55.72% to $115903.2 in 2022, then tumbled by 86.46% to $15691.5 in 2023, then sank by 1037.92% to -$147173.4 in 2024, then surged by 100.0% to -$0.0 in 2025.
The last three Other Operating Expenses figures came in at -$0.0 (Q3 2025), -$67.0 million (Q2 2025), and -$147173.4 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	Pharvaris	28.66 Bn	28.37 Bn	-

Download Data